» Articles » PMID: 18408574

Coagulation Defects Do Not Predict Blood Product Requirements During Liver Transplantation

Overview
Journal Transplantation
Specialty General Surgery
Date 2008 Apr 15
PMID 18408574
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In our experience, correction of coagulation defects with plasma transfusion does not decrease the need for intraoperative red blood cell (RBC) transfusions during liver transplantation. On the contrary, it leads to a hypervolemic state that result in increased blood loss. A previous study has shown that plasma transfusion has been associated with a decreased 1-year survival rate. The aim of this prospective study was to evaluate whether anesthesiologists could reduce RBC transfusion requirements during liver transplantation by eliminating plasma transfusion.

Methods: Two hundred consecutive liver transplantations were prospectively studied over a 3-year period. Patients were divided into two groups: low starting international normalized ratio (INR) value <1.5 and high INR > or =1.5. Low central venous pressure was maintained in all patients before the anhepatic phase. Coagulation parameters were not corrected preoperatively or intraoperatively in the absence of uncontrollable bleeding. Phlebotomy and auto transfusion of blood salvaged were used following our protocol. Independent variables were analyzed in both univariate and multivariate fashion to find a link with RBC transfusions or decreased survival rate.

Results: The mean number of intraoperative RBC units transfused was 0.3+/-0.8. Plasma, platelet, albumin, and cryoprecipitate were not transfused. In 81.5% of the patients, no blood product was used during their transplantation. The average final hemoglobin (Hb) value was 91.2+/-15.0 g/L. There were no differences in transfusional rate, final Hb, or bleeding between two groups (low or high INR values). The overall 1-year survival rate was 85.6%. Logistic regression showed that avoidance of plasma transfusion, phlebotomy, and starting Hb value were significantly linked to liver transplantation without RBC transfusion. The need for intraoperative RBC transfusion and Pugh's score were linked to the decreased 1-year survival rate.

Conclusion: The avoidance of plasma transfusion was associated with a decrease in RBC transfusions during liver transplantation. There was no link between coagulation defects and bleeding or RBC or plasma transfusions. Previous reports indicating that it is neither useful nor necessary to correct coagulation defects with plasma transfusion before liver transplantation seem further corroborated by this study. We believe that this work also supports the practice of lowering central venous pressure with phlebotomy to reduce blood loss, during liver dissection, without any deleterious effect.

Citing Articles

INTERNATIONAL NORMALIZED RATIO AND ACTIVATED PARTIAL THROMBOPLASTIN TIME DO NOT PREDICT PLASMA TRANSFUSION IN LIVER TRANSPLANTATION.

Marinho D, Rocha Filho J, Figueira E, Fernandes C, Detsch Junior R, Garcia J Arq Bras Cir Dig. 2025; 37():e1855.

PMID: 39813557 PMC: 11729538. DOI: 10.1590/0102-6720202400061e1855.


An overview of unresolved issues in the perioperative management of liver transplant patients.

Mittal S, Bhardwaj M, Shekhrajka P, Goyal V, Nimje G, Kanoji S Korean J Transplant. 2023; 37(4):221-228.

PMID: 38115164 PMC: 10772275. DOI: 10.4285/kjt.23.0061.


Viscoelastometry to Manage Bleeding in Liver Disease.

Wilson S, Joseph J, Danta M, Rabbolini D Cureus. 2023; 15(7):e41401.

PMID: 37546051 PMC: 10402654. DOI: 10.7759/cureus.41401.


Blood products and liver transplantation: A strategy to balance optimal preparation with effective blood stewardship.

Little C, Leverson G, Hammel L, Connor J, Al-Adra D Transfusion. 2022; 62(10):2057-2067.

PMID: 35986654 PMC: 9575510. DOI: 10.1111/trf.17074.


Association of Phlebotomy on Blood Product Transfusion Requirements During Liver Transplantation: An Observational Cohort Study on 1000 Cases.

Massicotte L, Hevesi Z, Zaouter C, Thibeault L, Karakiewicz P, Roy L Transplant Direct. 2022; 8(4):e1258.

PMID: 35372673 PMC: 8963830. DOI: 10.1097/TXD.0000000000001258.